CNS Pharmaceuticals, Inc. announced a 1-for-12 reverse stock split effective from July 22, 2025, reducing authorized common shares from 300 million to 25 million. The filing on July 17, 2025, includes details on the impacts to net loss per share and outstanding shares for previous fiscal periods.